胰腺导管腺癌MRI特征与KRAS突变状态的相关性
研究纳入308例经手术确诊且有基因检测数据的胰腺导管腺癌患者,比较KRAS突变型(258例)与非突变型(50例)的MRI特征、临床病理及预后。KRAS突变型表现为更高比例的糖尿病、病理周围神经浸润和pN分期,环状强化和更大肿瘤尺寸与KRAS突变相关,且总生存率更差。
要点
- 环状强化(OR=2.039)和更大肿瘤尺寸(OR=3.286)与KRAS突变型PDAC相关。
- KRAS突变型PDAC的1、3、5年总生存率分别为89.9%、45.4%、23.2%,低于非突变型的95.1%、60.4%、60.4%(P=0.045)。
- KRAS突变型PDAC伴更高比例的糖尿病(OR=2.450)、病理周围神经浸润(OR=2.296)和pN分期(OR=2.006)。
核心结论
- KRAS突变型PDAC具有独特的临床病理特征,预后更差;MRI上的环状强化和更大肿瘤尺寸是与KRAS突变型PDAC相关的特征。
研究设计与样本
- 研究纳入2016年1月至2023年12月期间1474例病理确诊的PDAC患者,最终纳入308例有基因检测数据和MRI检查且经手术确诊的患者(中位年龄67岁,IQR 59-72;男183例,女125例),分为KRAS突变型(258例)和非KRAS突变型(50例),比较两组增强MRI特征、临床病理及预后。
关键影像表现/征象
- 环状强化与KRAS突变型PDAC相关(OR=2.039,95%CI 1.053-3.951,P=0.035)。
- 更大肿瘤尺寸与KRAS突变型PDAC相关(OR=3.286,95%CI 1.523-7.089,P=0.002)。
诊断标准与关键数值
- KRAS突变型PDAC相关MRI特征:环状强化(OR=2.039,95%CI 1.053-3.951,P=0.035)和更大肿瘤尺寸(OR=3.286,95%CI 1.523-7.089,P=0.002)。
- KRAS突变型PDAC相关临床病理特征:糖尿病(OR=2.450,95%CI 1.151-5.212,P=0.020)、病理周围神经浸润(OR=2.296,95%CI 1.083-4.867,P=0.030)、pN分期(OR=2.006,95%CI 1.012-3.976,P=0.046)。
- KRAS突变型PDAC的1、3、5年总生存率分别为89.9%、45.4%、23.2%,非KRAS突变型分别为95.1%、60.4%、60.4%(P=0.045)。
临床应用与阅片要点
- MRI上观察到环状强化和较大肿瘤尺寸时,可能提示KRAS突变型PDAC。
- KRAS突变型PDAC患者合并糖尿病、病理周围神经浸润和更高pN分期的比例更高,预后更差。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate MRI features associated with KRAS mutation status in PDAC and their clinical implications.
MATERIALS AND METHODS: In our study, 1474 patients pathologically confirmed PDAC patients between January 2016 and December 2023 were evaluated. Patients with genetic testing (KRAS mutation status) and MRI examination were enrolled and grouped as KRAS-mutated PDAC and non-KRAS-mutated PDAC. Contrast-enhanced MRI features, clinicopathologic findings, and prognosis were compared between two groups.
RESULTS: A total of 308 surgically confirmed PDAC patients (median age, 67 years [IQR, 59, 72]; 183 male and 125 female) with genetic testing data were included, of which 258 had KRAS-mutated PDAC and 50 had non-KRAS-mutated PDAC. KRAS-mutated PDAC demonstrated distinct clinicopathological characteristics, including higher rates of diabetes (OR, 2.450, 95% CI, 1.151-5.212, P = 0.020), pathological peripheral nerve infiltration (OR, 2.296, 95% CI, 1.083-4.867, P = 0.030), and pN stage (OR, 2.006, 95% CI, 1.012-3.976, P = 0.046). The 1-, 3-, 5-year OS rate was worse for KRAS-mutated PDAC (89.9%, 45.4%, 23.2% vs. 95.1%, 60.4% 60.4%, P = 0.045). Rim enhancement (OR = 2.039, 95% CI: 1.053, 3.951, P = 0.035) and larger tumor size (OR = 3.286, 95% CI: 1.523, 7.089, P = 0.002) were identified as distinctive MRI features for KRAS-mutated PDAC.
CONCLUSION: KRAS-mutated PDAC presents unique clinical and pathological features and is associated with poorer prognosis. Rim enhancement and larger tumor size on MRI were identified as features associated with KRAS-mutated PDAC.
引用
- Shen J, Wang X, Yu K, et al. Correlation of MRI characteristics with KRAS mutation status in pancreatic ductal adenocarcinoma. Abdom Radiol (NY). 2025. PMID: 40156607. doi:10.1007/s00261-025-04888-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。